Pfizer and Biotech COVID Vaccine ’90 Per Cent Effective’
Pfizer and BioNTech have announced positive efficacy results from the third phase, late-stage study of their potential Covid-19 vaccine, which was found to be more than 90 per cent effective.
Pfizer chairman and chief executive Albert Bourla hailed “a first but critical step” in the project to “deliver a safe and effective vaccine”.
However, he added: “It’s important to note that we cannot apply for FDA Emergency Use Authorization based on these efficacy results alone. More data on safety is also needed, and we are continuing to accumulate that safety data as part of our ongoing clinical study.
“We estimate that a median of two months of safety data following the second and final dose of the vaccine candidate – required by FDA’s guidance for potential Emergency Use Authorization – will be available by the third week of November.”
Thousands of people volunteers to participate in the clinical trial.
Bourla said: “We look forward to sharing additional updates in the coming weeks and will continue to work closely with regulatory authorities to provide access to our anticipated vaccine for those who need it most.”